Neurogene Inc. (NGNE)

Neurogene's stock price has fluctuated due to market trends and company-specific developments. Declines occurred due to sector-wide pressure and analyst commentary, while positive momentum followed the recovery from a 52-week low and positive analyst coverage. A $200 million PIPE financing was announced in November 2024, providing a cash runway into the second half of 2027. Anticipated 2026 key milestones for NGN-401 were announced in January 2026, including the expectation of presenting interim data from the Phase 1/2 trial in mid-2026.

Traditional demand seasonality is not applicable to Neurogene, Inc.'s products. Demand is driven by the prevalence of the rare diseases they target and the progress of their clinical trials and regulatory approvals.

Neurogene, Inc. is a clinical-stage biotechnology company focused on developing genetic medicines for rare neurological diseases. Their lead product candidates include NGN-401, an investigational AAV9 gene therapy for Rett syndrome, and NGN-101, a conventional gene therapy for CLN5 Batten disease. The company was founded in 2018 by CEO Dr. Rachel L. McMinn.

Neurogene, Inc. is headquartered in New York, NY, and operates a CGMP manufacturing facility in Houston, Texas.

Neurogene's brand reputation is shaped by its mission and clinical progress in developing genetic medicines for rare neurological diseases. Positive developments, such as NGN-401 showing strong safety and efficacy for Rett syndrome, contribute to a favorable perception. The expansion of its U.S. clinical footprint and strong caregiver demand also reflect positively on its standing.

Institutional investors hold approximately 52.37% of Neurogene, Inc.'s stock, with major shareholders including Samsara BioCapital, LLC, RTW Investments, LP, and Redmile Group, LLC. Individual and insider ownership also exists, with transactions by key executives in 2025.